Taclonex suspension Uses

Is this medication very expensive?
sponsored

What is Taclonex suspension?

Taclonex suspension contains a combination of Taclonex suspension and Calcipotriene (Taclonex suspension suspension). Taclonex suspension is a steroid. It prevents the release of substances in the body that cause inflammation. Calcipotriene (Taclonex suspension suspension) is a form of vitamin D. It works by decreasing the rate of skin cell reproduction.

Taclonex suspension topical (for the skin) is a combination medicine used to treat plaque psoriasis.

Adults may use the suspension (liquid) form of this medicine on the skin or the scalp. The liquid may be used only on the scalp in children who are at least 12 years old.

Taclonex suspension topical ointment should be used only on the skin and only by adults.

Taclonex suspension indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended.

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment should not be applied to the face, axillae or groin.

How should I use Taclonex suspension?

Use Taclonex suspension exactly as it was prescribed for you. Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended. Do not use Taclonex suspension to treat any condition that has not been checked by your doctor.

Do not take Taclonex suspension by mouth.

Topical medicine is for use only on the skin. Do not use in the vagina.

Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.

Wash your hands before and after applying this medicine, unless you are using the medicine to treat the skin on your hands.

Shake the Taclonex suspension suspension (liquid) just before using it.

Apply Taclonex suspension once daily to the affected skin and rub it in gently. Do not spread the medicine over a large skin area. Do not apply to areas of thinner skin (face, underarms, groin) unless your doctor tells you to.

Do not cover the treated skin area. Covering skin treated with a topical steroid can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.

If you use Taclonex suspension liquid:

If you use Taclonex suspension ointment: Do not use more than 100 grams (1 large tube) of the ointment in 1 week. Avoid treating an area that is larger than 30% or one-third of your entire body.

Ask your pharmacist if you have questions about how much to apply each time you use the medicine.

Taclonex suspension ointment can be applied daily for up to 4 weeks. The liquid can be used daily for up to 8 weeks. Follow your doctor's instructions about your individual treatment schedule.

Call your doctor if your skin condition does not improve after several days of treatment, or if it gets worse while using this medicine.

If you use Taclonex suspension long-term, you may need frequent medical tests.

Store at room temperature away from moisture and heat. Keep the bottle or tube tightly closed when not in use.

Stop using Taclonex suspension when your skin clears up, unless your doctor tells you otherwise.

Uses of Taclonex suspension in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

This product contains 2 drugs (Taclonex suspension and Calcipotriene (Taclonex suspension suspension)) and is used to treat psoriasis of the scalp. Some brands of this medication are also used to treat psoriasis on the body. Taclonex suspension is a very strong corticosteroid drug that helps decrease the swelling, redness, and itching of the skin that occurs with this condition. Calcipotriene (Taclonex suspension suspension), which is also known as calcipotriol in other countries, is a form of vitamin D. It works by slowing down the growth of skin cells so that they do not build up into thickened, scaly skin patches.

This medication should not be used if you have certain types of psoriasis (skin patches with pus-filled blisters, psoriasis with intense redness/shedding/oozing). Consult your doctor for more information.

This product is not recommended for use in children because they may be at an increased risk for side effects. See also Side Effects and Precautions sections.

How to use Taclonex suspension topical

Read the Patient Information Leaflet provided by your pharmacist before you start using this product and each time you get a refill. If you have any questions, consult your doctor or pharmacist.

This medication is for use on the scalp. Do not apply this product 12 hours before or after any chemical treatments to your hair. Shake the bottle well before use. Part your hair, apply the product only to the affected area(s) of the scalp, and gently rub in, usually once daily or as directed by your doctor. Wash your hands after using, but do not wash your hair right after applying this product. Avoid getting any medication in the eyes or ears. If this occurs, immediately rinse with plenty of water. Do not apply this product to the face, underarms, or groin area.

If your doctor has directed you to use this product on your body, follow your doctor's directions for how much to use and where to use it. Apply to affected areas and gently rub in. Wash your hands after using.

Do not use this medication more often or for longer than directed. Do not use more than 100 grams of this product a week unless directed and closely monitored by your doctor. Do not bandage, wrap, or cover the treated area unless your doctor instructs you to do so. Do not use this product on large areas of damaged skin. Following these instructions helps to reduce your risk of side effects.

Tell your doctor if your condition does not improve or if it worsens. It may take up to 2 weeks to see any improvement.

Taclonex suspension dosage

sponsored

Taclonex suspension Dosage

Generic name: Calcipotriene (Taclonex suspension suspension) HYDRATE 50ug in 1g, Taclonex suspension DIPROPIONATE 0.5mg in 1g

Dosage form: ointment

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Apply an adequate layer of Taclonex suspension® Ointment to the affected area(s) once daily for up to 4 weeks. Taclonex suspension® Ointment should be rubbed in gently and completely. Patients should wash their hands after applying Taclonex suspension®Ointment. Therapy should be discontinued when control is achieved.

Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week. Treatment of more than 30% body surface area is not recommended.

Taclonex suspension® Ointment should not be used with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Taclonex suspension® Ointment is not for oral, ophthalmic, or intravaginal use.

More about Taclonex suspension (Taclonex suspension / Calcipotriene (Taclonex suspension suspension) topical)

Consumer resources

Professional resources

Other formulations

Related treatment guides

Taclonex suspension interactions

See also:
What other drugs will affect Taclonex suspension?

sponsored

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Some products that may interact with this drug are:

other corticosteroid drugs (such as hydrocortisone, prednisone), other products containing Calcipotriene (Taclonex suspension suspension).

Taclonex suspension side effects

See also:
What are the possible side effects of Taclonex suspension?

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

The data described below reflect exposure to Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment in 2448 patients, including 1992 exposed for 4 weeks, and 289 exposed for 8 weeks. In the trials that included assessment of the effects of Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment on calcium metabolism following treatment durations of longer than 4 weeks are not known. The effects of Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment on the HPA axis following treatment durations of longer than 4 weeks have not been adequately studied. Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment was studied primarily in placebo- and active-controlled trials (N = 1176, and N = 1272, respectively). The population was 15-97 years old, 61% males and 39% females, mostly white (97%) and had a baseline disease severity ranging from mild to very severe. Most patients received once daily application, and the median weekly dose was 24.5 g.

The percentage of subjects reporting at least one adverse event was 27.1% in the Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment group, 33.0% in the Calcipotriene (Taclonex suspension suspension) group, 28.3% in the Taclonex suspension group, and 33.4% in the vehicle group.

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate)

Ointment

N=2448

Calcipotriene (Taclonex suspension suspension)

N=3197

Taclonex suspension

dipropionate

N=1164

Vehicle

N=470

Any Adverse Event 663 (27.1) 1055 (33.0) 329 (28.3) 157 (33.4)
Preferred Term # of subjects (%)
Pruritus 75 (3.1) 183 (5.7) 38 (3.3) 43 (9.1)
Headache 69 (2.8) 75 (2.3) 44 (3.8) 12 (2.6)
Nasopharyngitis 56 (2.3) 77 (2.4) 34 (2.9) 9 (1.9)
Psoriasis 30 (1.2) 47 (1.5) 14 (1.2) 5 (1.1)
Rash scaly 30 (1.2) 40 (1.3) 0 (0.0) 1 (0.2)
Influenza 23 (0.9) 34 (1.1) 14 (1.2) 6 (1.3)
Upper respiratory 20 (0.8) 19 (0.6) 12 (1.0) 3 (0.6)
tract infection 15 (0.6) 54 (1.7) 3 (0.3) 5 (1.1)
Erythema Application site 13 (0.5) 24 (0.8) 10 (0.9) 6 (1.3)
pruritus 11 (0.4) 60 (1.9) 8 (0.7) 5 (1.1)
Skin irritation 7 (0.3) 12 (0.4) 3 (0.3) 5 (1.1)
Pain Burning sensation 6 (0.2) 30 (0.9) 3 (0.3) 6 (1.3)

Adverse Events Reported by ≥ 1% of Subjects by Preferred Term

A lesional/perilesional adverse event was generally defined as an adverse event located ≤ 2 cm from the lesional border.

Lesional/Perilesional Adverse Events Reported by ≥ 1% of Subjects

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate)

Ointment

N=2448

Calcipotriene (Taclonex suspension suspension)

N=3197

Taclonex suspension

dipropionate

N=1164

Vehicle

N=470

Any Adverse Event 213 (8.7) 419 (13.1) 85 (7.3) 76 (16.2)
Preferred Term # of subjects (%)
Pruritus 69 (2.8) 170 (5.3) 31 (2.7) 41 (8.7)
Rash scaly 29 (1.2) 38 (1.2) 0 (0.0) 0 (0.0)
Application site pruritus 12 (0.5) 24 (0.8) 10 (0.9) 6 (1.3)
Erythema 9 (0.4) 36 (1.1) 2 (0.2) 4 (0.9)
Skin irritation 9 (0.4) 51 (1.6) 8 (0.7) 5 (1.1)
Burning sensation 6 (0.2) 25 (0.8) 3 (0.3) 5 (1.1)

For subjects who reported lesional/perilesional adverse events, the median time to onset was 7 days for Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment, 7 days for Calcipotriene (Taclonex suspension suspension), 5 days for Taclonex suspension dipropionate, and 3 days for vehicle.

Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence, folliculitis, rash papular, rash pustular, and skin hypopigmentation. Skin atrophy, telangiectasia and skin hyperpigmentation were reported infrequently (0.1%).

In a separate study, patients (N=207) with at least moderate disease severity were given Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment intermittently on an “as needed” basis for up to 52 weeks. The median use was 15.4 g per week. The effects of Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment on calcium metabolism were not studied and the effects on the HPA axis were not adequately studied. The following adverse reactions were reported by 1% or more of the patients: pruritus (7.2%), psoriasis (3.4%), skin atrophy (1.9%), folliculitis (1.4%), burning sensation (1.4%), skin depigmentation (1.4%), ecchymosis (1.0%), erythema (1.0%) and hand dermatitis (1.0%). One case of a serious flare-up of psoriasis was reported.

Development of pustular psoriasis has been reported as an adverse reaction during and following use of Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment.

Taclonex suspension contraindications

See also:
What is the most important information I should know about Taclonex suspension?

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment is contraindicated in patients with known or suspected disorders of calcium metabolism.

Taclonex suspension® (Calcipotriene (Taclonex suspension suspension) and Taclonex suspension dipropionate) Ointment is contraindicated in patients with erythrodermic, exfoliative and pustular psoriasis.

Active ingredient matches for Taclonex suspension:

Betamethasone/Calcipotriene


List of Taclonex suspension substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Ointment; Topical; Betamethasone Dipropionate 0.064%; Calcipotriol Hydrate 0.005% (Warner chilcott)
100 gram in 1 tube (Warner chilcott)
3 gram in 1 tube (Warner chilcott)
60 gram in 1 tube (Warner chilcott)
Suspension; Topical; Betamethasone Dipropionate 0.064%; Calcipotriol Hydrate 0.005%

References

  1. DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "betamethasone". http://www.drugbank.ca/drugs/DB00443 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Taclonex suspension are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Taclonex suspension. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved